[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"articular-cartilage-defect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:articular-cartilage-defect":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,78,108,128,155,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100330956","phase-3-a-study-of-maci-in-patients-aged-10-to-17-years-with-symptomatic-chondral-or-osteochondral-defects-of-the-knee-100330956",false,"NCT03588975","A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee","A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee","PEAK","Inclusion Criteria:\n\n* Symptomatic cartilage or osteochondral defects\n* One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and\u002For trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).\n\n  1. Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.\n  2. Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.\n* At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and\u002For the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.\n* Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.\n* Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.\n* Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.\n* Written informed consent\n\nExclusion Criteria:\n\n* Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)\n* Previous investigational drug or device use within 3 months prior to Screening\n* Avascular necrosis of the target knee (other than potential OCD lesion to be treated)\n* Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate\n* ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion\n* Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)\n* Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint\n* Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)\n* Known history of septic arthritis in the index knee joint\n* Current malignancy or treatment for malignancy within the past 5 years\n* Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin\n* Females who are pregnant or lactating\n* Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:\n\n  * Any condition that has potential for negatively impacting intra or postoperative course\n  * Conditions that limit compliance with rehabilitation program\n  * Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function\n  * Any condition, psychiatric or otherwise, that would preclude informed consent\u002Fassent, consistent follow-up, or compliance with any aspect of the study\n  * Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance","ALL","10 Years","17 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.",[28,29,30,31],"Chondral Defect","Osteochondritis Dissecans (OCD)","Articular Cartilage Defect","Articular Cartilage Disorder of Knee",[33,34,35],"OCD","cartilage","cartilage defect","RECRUITING","2026-06-19",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2018-10-24",{"date":44,"type":22},"2030-02",{"name":46,"class":47},"Vericel Corporation","INDUSTRY",12,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100586427","phase-3-a-study-of-maci-in-patients-aged-17-to-65-years-with-symptomatic-chondral-or-osteochondral-defects-of-the-ankle-100586427","NCT06915233","A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle","A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients With Symptomatic Chondral or Osteochondral Lesions of the Talus (MASCOT)","MASCOT","Inclusion Criteria:\n\n1. Age 17 to 65 at the time of planned randomization visit (Visit 2).\n2. One or more symptomatic chondral or osteochondral lesion\u002Fs as defined by FAOS Pain score ≤ 50 and FAOS Function (SRA) score ≤ 50.\n3. International Cartilage Repair Society (ICRS) Score Grade 3 or 4 chondral or osteochondral lesion\u002Fs located on the talus with or without cysts, including shoulder lesions (lesions on the talar neck), and amenable to treatment with the surgical procedure specified at randomization.\n4. At least 1 lesion ≥ 1.2 cm².\n5. Written informed consent and assent (as applicable) per Institutional Review Board (IRB) requirements.\n6. Participant will refrain from using Non-steroidal Anti-inflammatory Drugs (NSAIDS) for 12 weeks post-study treatment. (Post-surgical use of low-dose aspirin for clot prevention is acceptable).\n7. Participant will restrict pain medication to over-the-counter analgesics (NSAIDs or acetaminophen\u002Fparacetamol) after 12 weeks post-study treatment.\n8. Participant must have Hematocrit ≥30.0%; White Blood Cell count ≤14,000 cells\u002FμL; Platelet Count ≥50,000 platelets\u002FμL; Creatinine ≤2.0 mg\u002FdL; and International Normalized Ratio (INR) ≤1.6.\n\nExclusion Criteria:\n\n1. Lesions with an underlying bony defect depth of \\> 5 mm.\n2. Any surgery on the target joint within 24 weeks prior to Visit 1 (not including diagnostic ankle arthroscopy).\n3. Previous investigational drug, biologic or device use within 12 weeks prior to Visit.\n4. Avascular necrosis of the target ankle.\n5. Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target ankle joint.\n6. Participant with \"kissing lesions\" (bipolar lesions, involving both the tibia and talus), or with bilateral lesions in both ankles.\n7. Participant with lesions that require an osteotomy procedure to allow for MACI implantation as determined at the time of ankle arthroscopy (Visit 2).\n8. Concomitant systemic inflammatory diseases or other conditions that affect the joints (e.g., rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis).\n9. History of advanced or severe osteoarthritis of the ankle as determined by prior surgical history confirming no joint space (i.e., \"bone on bone\") or radiographic evidence of Modified Kellgren-Lawrence Grade 4 arthritis (i.e., osteophytes on lateral and medial malleoli and at the tibiotalar joint margins, narrowing of the joint space width \\> 50%, and tibiotalar sclerosis), Van Dijk Grade III (i.e., total or subtotal destruction of the joint space) or the equivalent.\n10. Known history of septic arthritis in the target ankle joint within 1 year prior to Visit 1.\n11. Current malignancy or treatment for malignancy within the past 5 years prior to Visit 1, excluding non-melanoma skin cancer.\n12. Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin.\n13. Females who are pregnant or lactating.\n14. Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:\n\n    1. Any condition that has potential for negatively impacting intra- or postoperative course (e.g., uncontrolled diabetes, heavy smoking). - Uncontrolled diabetes is defined as hemoglobin A1c (HbA1c) ≥8.0% and\u002For fasting plasma glucose \\>250 mg\u002FdL (13.9 mmol\u002FL) within the last 90 days prior to Screening Visit 1 - Heavy smoking is defined as current smoker with use of ≥20 cigarettes per day (≥1 pack\u002Fday) at the time of Screening Visit 1.\n    2. Conditions that limit compliance with rehabilitation program.\n    3. Any condition that has potential for significantly limiting participant's ability to assess postoperative ankle function.\n    4. Any condition, psychiatric or otherwise, that would preclude informed consent\u002Fassent, consistent follow-up, or compliance with any aspect of the clinical trial.\n    5. Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance.\n    6. Any abnormal screening blood work that the Investigator deems clinically significant in addition to the parameters delineated in Inclusion Criterion #8.\n15. Injection of hyaluronic acid (HA), platelet-rich plasma (PRP), and\u002For corticosteroids in the target ankle within 90 days prior to Visit 1.","65 Years",{"count":59,"type":22},309,[25],"The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus.",[28,30],[64,65,66,67,68],"Bone Diseases","Musculoskeletal Diseases","Connective Tissue Diseases","Osteochondritis","Cartilage Diseases","2026-05-21",{"date":71,"type":40},"2026-05-27",{"date":73,"type":22},"2026-05",{"date":75,"type":22},"2030-07",{"name":46,"class":47},4,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100489352","study-comparing-two-methods-for-the-treatment-of-large-chondral-and-osteochondral-defects-of-the-knee-100489352","NCT05651997","Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee","Randomized Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee: Augmented Microfracture Technique vs. 3rd Generation of ACI","Inclusion Criteria:\n\n* Patients aged between 15-50 years\n* Symptomatic chondral and osteochondral defect, grade III and IV according to the ICRS classification, and size between 2.5 and 15 cm2\n* Failure of a conservative treatment\n* Patient in good general condition, documented by an ASA score ≤ 2 (American Society of Anesthesiologists)\n* Patient considered compliant and able to participate in rehabilitation and pre- and post-operative follow-up\n* Consent to participate in the study\n\nExclusion Criteria:\n\n* All inflammatory and synovial pathologies\n* Diffuse or mirror lesions\n* An unfavorable biomechanical environment\n* Obesity grade II or higher, with a BMI\\>35 kg\u002Fm2\n* Active smoking\u002F active drug dependency (hard drugs)\n* Poor compliance\n* The patient is already part of another clinical trial that may compromise the present study\n* Vulnerable populations (except minors aged 15-18 years)\n* Presence of open growth plate (15-18 years)\n* Pregnancy or planned pregnancy during the study (MRI-related contra-indication)\n* Proven allergy to penicillin and gentamicin (for MACT group) and porcine collagen (for both groups)\n\nFor final inclusion, an additional exclusion criteria will be assessed after randomization:\n\n\\- Positive to HIV, HBV, HCV, syphilis.","15 Years","50 Years",{"count":88,"type":22},80,[90],"NA","The major objective of this study is to evaluate the efficacy of the MACT versus the AMT for the treatment of large cartilage defects in patellofemoral and femorotibial injuries.",[30,28,67],[94,95],"Cellular therapy","Human articular chondrocytes","NOT_YET_RECRUITING","2026-03-10",{"date":99,"type":40},"2026-03-12",{"date":101,"type":22},"2026-12",{"date":103,"type":22},"2032-06-01",{"name":105,"class":106},"Centre Hospitalier Universitaire Vaudois","OTHER",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100385267","introduction-of-aci-for-cartilage-repair-100385267","NCT04296487","Introduction of ACI for Cartilage Repair","Introduction of Autologous Chondrocyte Implantation Procedure for the Treatment of Chondral Defect in the Knee","Inclusion Criteria:\n\n1. Age between 15 and 50.\n2. Lesions classified as ICRS Grade III or IV and smaller than 15 cm2\n3. Lesions that have failed prior therapy (conservative or surgical treatment ≥ six months)\n4. Subjects who understand and sign the consent form for this study\n\nExclusion Criteria:\n\n1. Body mass index (BMI) of 35 or more\n2. Osteoarthritis or rheumatoid arthritis\n3. Diffuse lesion\n4. Uncorrected mal-alignment, ligamentous instability, or meniscal tear\n5. Presence of growth cartilage (15-18 years old)\n6. Active smoking or drug consumption\n7. Women who are pregnant\n8. Positive serology for HIV-1 or HIV-2, Hepatitis B and C and syphilis\n9. Proven allergy to porcine collagen, penicillin and gentamicin\n10. Poor compliance",{"count":116,"type":22},218,[90],"This study was aimed to evaluate effectiveness and safety of autologous chondrocyte suspension for treatment of knee articular cartilage defects.",[30,28,67],{"date":121,"type":40},"2026-03-11",{"date":123,"type":40},"2017-09-01",{"date":125,"type":22},"2030-09",{"name":105,"class":106},1,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":127},"100470148","phase-1-amic-compared-with-microfracture-for-focal-articular-cartilage-damage-of-the-hip-100470148","NCT05402072","AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip","Autologous MatRix-Induced ChondrogenEsis ComPared With Microfracture for Focal ArtIcular CaRtilage Damage of the Hip (REPAIR): A Pilot Randomized Controlled Trial","REPAIR","Inclusion Criteria:\n\n1. All patients aged 18-55 years\n2. Hip pain lasting 6 months or more with no relief from documented non-operative modalities\n3. Focal articular cartilage defects of the acetabulum on MRI, confirmed to be full thickness (International Cartilage Regeneration and Joint Preservation Society (ICRS) grade 3 or 4) during arthroscopic examination\n4. Focal acetabular articular cartilage lesions measuring between 3 cm2 and 25 cm2 on MRI and confirmed on arthroscopic examination\n5. Patient agrees to participate in the study-specific postoperative rehabilitation protocol\n6. Patient can speak, read, and understand the language of the site\n7. Patient has provided informed consent\n\nExclusion Criteria:\n\n1. Cartilage defects of the femoral head\n2. Previous surgery on the study hip\n3. Traumatic chondral injury of the hip from a single event\n4. Presence of advanced osteoarthritis (Tonnis grade 3) or any other acute or chronic inflammatory joint disease\n5. Known hypersensitivity or allergy to porcine collagen\n6. Acute or chronic infection at the surgical site\n7. Evidence of hip dysplasia (i.e., lateral centre edge angle \\\u003C 20˚)\n8. Evidence of acetabular over coverage such as coxa profunda or coxa protrusion\n9. Immunosuppressive or anti-proliferative medication use\n10. Chronic pain syndromes\n11. Significant medical co-morbidities (requiring assistance for activities of daily living (ADLs))\n12. History of paediatric hip disease\n13. Uncontrolled diabetes\n14. Contraindications to MRI imaging (e.g. claustrophobia)\n15. Patient is involved in ongoing legal or workplace claims\n16. Patient is incarcerated\n17. Patient is pregnant or breastfeeding\n18. Patient who will likely have problems, in the judgement of the investigator, with maintaining follow-up\n19. Any other reason(s) the investigator feels is relevant for excluding the patient","18 Years","55 Years",{"count":139,"type":22},40,[141],"PHASE1","This is a pilot multi-centre RCT of 40 patients (ages 18-55 years, inclusive) undergoing primary hip arthroscopy with a focal articular cartilage defect of the acetabulum to compare the effect of using autologous matrix-induced chondrogenesis (AMIC) in comparison to microfracture on hip function, health-related quality of life, hip pain, cartilage regeneration, health utility, and any adverse events at 2 years. Follow-up will occur at 6 weeks, 6 months, 12 months, 18 months, and 24 months post-surgery.",[144,30,145],"Hip Arthroscopy","Microfractures","2025-09-22",{"date":148,"type":40},"2025-09-24",{"date":150,"type":40},"2023-03-13",{"date":152,"type":22},"2027-01-01",{"name":154,"class":106},"McMaster University",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":127},"100511668","autologous-costal-osteochondral-transplantation-for-talar-osteochondral-lesions-100511668","NCT05942430","Autologous Costal Osteochondral Transplantation for Talar Osteochondral Lesions","Evaluation of the Effectiveness and Safety of Autologous Costal Osteochondral Transplantation in the Treatment of Talar Osteochondral Lesions: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Symptomatic Hepple stage V talar osteochondral lesions with a lesion depth ≥5 mm and an AOFAS score ≤80 points;\n* Failed conservative treatment for at least 6 months;\n* Unilateral talar osteochondral lesions without corresponding lesions on the tibial side;\n* Willingness to participate in this clinical trial and signing an informed consent form.\n\nExclusion Criteria:\n\n* Combined with lower limb deformity.\n* Combined with hip or knee joint diseases.\n* Combined with ipsilateral ankle arthritis with joint space narrowing .\n* Diagnosis of gouty arthritis of the ankle joint.\n* Combined with osteoporosis (T score \\\u003C-2.5).\n* Other conditions considered inappropriate for participation in this clinical trial by the researchers.","60 Years",{"count":164,"type":22},50,[90],"The goal of this clinical trial is to evaluate the effectiveness and safety of autologous costal osteochondral transplantation in the treatment of Hepple Stage V talar osteochondral lesions, compared with autologous osteoperiosteal transplantation. The main question it aims to answer is:\n\n• Whether autologous costal osteochondral transplantation can achieve better clinical outcomes and cartilage repair quality with lower donor site morbidity than autologous osteoperiosteal transplantation in the treatment of Hepple Stage V talar osteochondral lesions.\n\nParticipants will be randomly assigned to the intervention group (undergoing autologous costal osteochondral transplantation) or the control group (undergoing autologous osteoperiosteal transplantation). Both groups of participants will receive the same postoperative rehabilitation process and follow-up evaluation.",[30],[169,170,171,172],"costa","autologous osteochondral transplantation","autologous osteoperiosteal transplantation","osteochondral lesion of the talus","2023-09-04",{"date":175,"type":40},"2023-09-06",{"date":177,"type":40},"2023-09-01",{"date":179,"type":22},"2028-02",{"name":181,"class":182},"The Third Affiliated Hospital of Southern Medical University","OTHER_GOV",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100419644","phase-2-phase-2-clinical-trial-of-cartilife-in-the-united-states-100419644","NCT04744402","Phase 2 Clinical Trial of CartiLife® in the United States","A Multi-Center, Open-Label, Phase 2 Trial to Evaluate the Efficacy and Safety of CartiLife® for Patients With Articular Cartilage Defects in the Knee","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following:\n\n1. Male or female subjects aged over 18 at the time of signing the Informed Consent form\n2. Subject who has a size of the relevant cartilage lesion ≥ 2 cm2 and ≤ 10 cm2 but with a defect area total volume ≤ 4 cm3\n3. Subject with isolated International Cartilage Repair Society (ICRS) Grade III or IV chondral lesion on articular cartilage\n4. Subject who has a lower extremity alignment within 5 degrees of the neutral weight bearing axis\n5. Subject who can move independently and has a mechanically stable knee (normal ligament status)\n6. Subject with intact or partial meniscus status (\\>50% of meniscus)\n7. Subject who has KOOS pain value less than 60 at baseline\n8. Subject who agrees to actively participate in a rehabilitation protocol and follow-up program\n9. Subject who is able to provide informed consent and comply with study requirements\n10. Subject who is willing to discontinue any nonsteroidal anti-inflammatory drugs (NSAIDs) except rescue medication (\\\u003C acetaminophen 4 g per day) 7 days prior to visit\n11. Subject who has Body Mass Index (BMI) ≤ 37 kg\u002Fm2\n12. Female and male subjects of childbearing potential who are willing to use adequate contraception methods for the duration of the trial.\n\nExclusion Criteria:\n\nIndividuals who meet any of the following will be excluded from participation in this study:\n\n1. Subject who has inflammatory articular diseases such as rheumatoid arthritis or gout or pseudogout\n2. Subject who has radiographic evidence of grade 4 osteoarthritis based on the Kellgren and Lawrence criteria\n3. Subject who has received an intra-articular treatment within the last 3 months\n4. Subject who has had a surgical procedure on the knees within the last 6 weeks (Subjects can be considered enrollment per the investigator's discretion)\n5. Subject who has a condition in another lower extremity joint that interferes with the function of the index knee\n6. Subject who would receive a concomitant surgical procedure on the knees at the time of the study treatment\n7. Subject whose articular cartilage defect is asymptomatic\n8. Subject who has any clinically significant disease, which is judged by the investigator to affect this clinical trial, including but not limited to diabetes not adequately controlled, bleeding diathesis or hematologic disease, endocrinopathies, cardiovascular disease, renal disease (severe renal impairment), autoimmune disease, inflammatory arthritis, and current infectious disease\n9. Subject with other diseases including tumors except for cartilaginous defects of joints\n10. Subject who has a history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin\n11. Subject who participates in concurrent trials or in previous trial within 30 days of signing informed consent\n12. Subject who has any radiation therapy or chemotherapy within 2 years prior to screening\n13. Subject who is currently pregnant or nursing\n14. Subject who has any degenerative muscular, connective tissue or neurological condition or other disease process that would interfere with healing or the evaluation of outcome measures.\n15. Subject with known HIV infection, active hepatitis C and\u002For hepatitis B infection\n16. Subject who has ligament instability \\> Grade 1\n17. Subject who is an active drug\u002Falcohol abuser or has a history of alcohol or drug abuse during the last two years.\n18. Subject who has significant lab abnormalities for the following parameters (If the value is within 10% of the listed laboratory exclusion criterion value and the value is considered not to be clinically significant by the investigator, the subject can be considered for enrollment):\n\n    * Serum ALT and AST \\> 3 x upper limit of normal\n    * Serum creatinine \\> 1.5 x upper limit of normal\n    * PT\u002FINR out of normal range\n    * Hemoglobin \\\u003C 10 g\u002FdL for female subject and hemoglobin \\\u003C 11 g\u002FdL for male subject\n    * Platelets out of normal range\n    * Hemoglobin A1c levels \\> 9%",{"count":191,"type":22},25,[193],"PHASE2","To evaluate the safety and efficacy of implanting pellet-type extracellular matrix-associated autologous chondrocytes (CartiLife®) obtained by cultivating costal chondrocytes of the subject with articular cartilage defects of the knee as a result of trauma or degeneration.",[30,196],"Articular Cartilage Degeneration","2023-08-24",{"date":199,"type":40},"2023-08-28",{"date":201,"type":40},"2020-10-28",{"date":203,"type":22},"2023-12",{"name":205,"class":47},"Biosolution Co., Ltd.",5]